Kitsawet Saethao/iStock via Getty Images
Vertex Pharmaceuticals (NASDAQ:VRTX) has received conditional marketing authorization from the European Commission for its gene editing therapy, Casgevy (exagamglogene autotemcel), developed with CRISPR Therapeutics (NASDAQ:CRSP).
Casgevy, a CRISPR/Cas9 gene-edited cell therapy, is approved for the treatment of patients who are 12 years